Shares of Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) have received a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $38.29.
Several equities analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wedbush upped their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Citigroup raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. William Blair started coverage on Vor Biopharma in a research note on Wednesday, October 21st. They set an “outperform” rating for the company. Finally, Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, October 31st.
Read Our Latest Report on Vor Biopharma
Vor Biopharma Price Performance
Vor Biopharma (NASDAQ:VOR – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). On average, equities research analysts predict that Vor Biopharma will post -2.74 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. Parallel Advisors LLC increased its position in Vor Biopharma by 29,640.0% during the third quarter. Parallel Advisors LLC now owns 1,487 shares of the company’s stock valued at $28,000 after acquiring an additional 1,482 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in Vor Biopharma by 40.3% in the third quarter. Global Retirement Partners LLC now owns 2,931 shares of the company’s stock valued at $56,000 after acquiring an additional 842 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Vor Biopharma in the third quarter valued at about $58,000. Fulcrum Asset Management LLP bought a new position in Vor Biopharma in the third quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Vor Biopharma by 25.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock worth $198,000 after purchasing an additional 2,171 shares during the last quarter. Institutional investors own 97.29% of the company’s stock.
Vor Biopharma Company Profile
Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.
See Also
- Five stocks we like better than Vor Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
